Skip to content Skip to footer

GLP 1 (Glucagon-Like Peptide-1): Mechanism, Research Applications and Handling Requirements

GLP 1, or glucagon-like peptide-1, is a peptide hormone of 30 amino acids in its main active form, GLP-1(7-36) amide, with a molecular weight of about 3.3 kilodaltons. It is produced from the proglucagon precursor and acts on the GLP-1 receptor, a class B G protein-coupled receptor. Researchers use it to study cyclic AMP signalling, glucose-dependent insulin secretion in pancreatic islet and beta-cell models, receptor pharmacology, and the enzymatic degradation of peptide hormones. This article describes its structure and discovery, its receptor mechanism, key published studies, laboratory applications, and the purity, storage and handling requirements that apply to the material.

What is GLP 1?

GLP 1 belongs to the incretin family of gut-derived peptides. It is secreted by L cells of the intestine and is encoded by the same gene as glucagon. The proglucagon precursor is processed differently in different tissues: in the pancreatic alpha cell it yields glucagon, and in the intestinal L cell it yields glucagon-like peptides. The principal active forms are GLP-1(7-36) amide and GLP-1(7-37), which differ by one C-terminal glycine and by the C-terminal group. The amide form has the single-letter sequence HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR, with an amidated C-terminus, and a mass of about 3,298 daltons. The numbering begins at 7 because residues 1 to 6 of the longer precursor fragment are removed during processing.

The discovery history runs through gene sequencing. In 1983, Bell and colleagues reported the structure of the human preproglucagon gene, which revealed that it encodes not only glucagon but also two further glucagon-like sequences. In the following years, Drucker, Habener and colleagues showed in 1987 that GLP-1 stimulates insulin gene expression and raises cyclic AMP in a rat islet cell line, and that the truncated forms were the active ones. A distinct but related peptide, exendin-4, was isolated from the venom of the Gila monster, a 39-residue peptide of about 4.2 kilodaltons that activates the same receptor and resists degradation, which is why it became a standard reference agonist.

Because native GLP-1 is destroyed within minutes in biological fluids, a family of modified analogues has been developed, including acylated and amino-acid-substituted versions. Some of these are authorised prescription medicines. A medicine and a research reagent are different regulatory categories even where the receptor target is shared, and UK buyers should check the current position with the Medicines and Healthcare products Regulatory Agency. Nothing in this article concerns use in people.

Mechanism of action

GLP 1 acts on the GLP-1 receptor, a class B member of the G protein-coupled receptor family with seven transmembrane domains. Binding follows a two-domain model: the C-terminal portion of the peptide engages the large extracellular domain of the receptor, while the N-terminal portion inserts into the transmembrane core and triggers activation. The receptor couples mainly to Gs, which activates adenylyl cyclase and raises intracellular cyclic AMP. Cyclic AMP then activates protein kinase A and the exchange protein Epac2, and these pathways, together with changes in calcium handling and ion channel activity, potentiate insulin granule exocytosis in beta cells. In experiments, this potentiation depends on the presence of elevated glucose, which is why assays of insulin secretion are run at defined glucose concentrations.

The receptor is expressed in pancreatic islets and in several other tissues, including parts of the nervous system, and its signalling is shaped by several further mechanisms. At higher agonist concentrations, coupling to Gq and calcium mobilisation has been reported, and recruitment of arrestins mediates desensitisation and internalisation. Different agonists can stabilise different receptor conformations, a phenomenon known as biased agonism, which has made the receptor a prominent subject of signalling research.

Degradation is the second part of the mechanism and the main practical constraint. Dipeptidyl peptidase-4 removes the N-terminal His-Ala dipeptide, yielding a fragment with far lower receptor activity, and neprilysin and other proteases also act on the peptide. The half-life of native GLP-1 in plasma is only a couple of minutes, so incubation times, protease inhibitors and the choice between native and stabilised analogues are central design decisions in any experiment.

What the research shows

Four areas of published work underpin the use of GLP 1 in laboratories. Readers should consult the primary papers for methods and data.

The first is the 1983 characterisation of the human preproglucagon gene by Bell and colleagues in Nature. By determining the structure of the gene, the work showed that glucagon and two glucagon-like peptides are encoded together, which provided the basis for identifying GLP-1 as a distinct hormone. It is described here in general terms, and the original paper should be consulted for the sequence analysis.

The second is the 1987 study by Drucker, Philippe, Mojsov, Chick and Habener in the Proceedings of the National Academy of Sciences, which examined GLP-1 in a rat islet cell line. The authors reported that the peptide stimulated insulin gene expression and increased cyclic AMP levels in the cells, a result that tied the peptide to the cyclic AMP pathway in a controlled cell-culture model. Details of concentrations and controls are in the original paper.

The third is the 1992 expression cloning of the receptor by Bernard Thorens, also in the Proceedings of the National Academy of Sciences. A cDNA for the GLP-1 receptor was isolated by transient expression of a rat pancreatic islet cDNA library in COS cells, and the transfected receptor bound GLP-1 with high affinity and was coupled to activation of adenylate cyclase. The receptor did not bind related peptides such as glucagon, gastric inhibitory peptide, vasoactive intestinal peptide or secretin, and it showed sequence homology only with the receptors for secretin, calcitonin and parathyroid hormone, which defined a new family of G protein-coupled receptors. The record is on PubMed.

The fourth is a 2024 open-access market-surveillance study of semaglutide products sold online without a prescription, which is relevant to the analytical side of this field. It concerns an unregulated medicine and not a research reagent, but it measured what vials actually contained. The authors judged all purchased vials to be probable substandard and falsified products, and found that semaglutide content exceeded the labelled amount by 28.56% to 38.69% when measured by liquid chromatography coupled with mass spectrometry. The finding illustrates that a label is not evidence of content, and the paper is on PubMed Central.

Research applications

GLP 1 and its analogues are used in several well-defined laboratory contexts. In receptor pharmacology, they serve as agonists in binding and signalling assays on cell lines expressing the GLP-1 receptor, such as transfected human embryonic kidney or Chinese hamster ovary cells, where cyclic AMP accumulation, calcium flux and arrestin recruitment are the usual readouts. Comparisons between native GLP-1, exendin-4 and modified analogues are used to examine potency, efficacy and biased signalling.

In islet and beta-cell research, insulin-secreting lines such as INS-1 and MIN6, as well as isolated islets, are used to study glucose-stimulated insulin secretion and its potentiation, with glucose concentration and incubation time carefully controlled. In enzymology, native GLP-1 is a classic substrate for studying dipeptidyl peptidase-4 and other proteases, and degradation assays monitored by HPLC or mass spectrometry measure peptide half-life under different conditions. In structural biology, the peptide is used in studies of ligand binding and receptor activation.

In analytical chemistry, GLP-1 and its analogues are reference materials for developing liquid chromatography and mass-spectrometry methods, including methods for detecting falsified or substandard products. For that purpose, identity and purity documentation is as important as in any cell-based study.

UK purchasers should also consider the regulatory framework. Medicines containing GLP-1 receptor agonists such as semaglutide and tirzepatide are prescription-only, and the MHRA decides case by case whether a product is a medicine, looking at labelling, packaging, promotional literature and advertisements, including websites. Its borderline products guidance explains the approach. A research-use-only designation carries weight only when everything about how the material is supplied is consistent with laboratory use. This is general information, not legal advice, and institutions should involve their compliance staff.

Purity, storage and handling

Verification begins with reversed-phase HPLC, usually with UV detection at 214 or 220 nm, which separates the target from deletion sequences, truncated chains and incompletely deprotected by-products and reports purity as the percentage of total peak area belonging to the target. A figure of 98% or higher is commonly specified for cell-based and receptor assays. HPLC does not prove identity, so it should be paired with mass spectrometry confirming that the observed mass matches the theoretical value. For GLP 1 this matters in a specific way, since the 7-36 amide, the 7-37 acid and the longer precursor forms are closely related, and a certificate must state which form was supplied and show the matching mass.

A batch-specific certificate of analysis matters because synthesis is never perfectly repeatable. Two lots of the same sequence can differ in purity, counter-ion content, water content and net peptide content, and a generic specification sheet cannot capture that variation. A proper certificate lists the lot number, chromatogram, mass-spectrometry result and analysis date, so a result can be traced to a specific vial. Because native GLP-1 is prone to aggregation in solution and exists in several closely related forms, batch-level HPLC and mass-spectrometry verification matters more here than with simpler, more stable peptides. UK laboratories sourcing GLP 1 should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and the supplier checks are set out in How to buy best peptides.

Lyophilised peptides are most stable when dry, sealed and cold. Storage at -20°C is the usual recommendation for the long term, and -80°C is sometimes preferred for sensitive sequences. Vials should be brought to room temperature in a desiccator before opening, because condensation introduces moisture that promotes hydrolysis. The sequence contains no cysteine or methionine, so it is less prone to oxidation than many peptides, but it carries a tryptophan, glutamine and aspartate residues that can undergo photo-oxidation, deamidation and isomerisation over long periods.

Reconstituted peptides are far less stable than the dry powder. Stock solutions are normally prepared in sterile water or a suitable buffer, divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Native GLP-1 has a tendency to aggregate, and its solubility is lowest near its isoelectric point, so buffer pH should be chosen with care and solutions inspected for turbidity. Low-binding tubes reduce adsorption losses at low concentrations. In cell assays, the half-life in the medium is short, so experimental design must account for degradation. Stability in solution is sequence-specific, and researchers should consult supplier data and validate it under their own conditions.

Light sensitivity is a further consideration. Tryptophan and tyrosine can undergo photo-oxidation, so vials are best stored in the dark or in amber glass, and bench exposure should be kept short. Each aliquot should be labelled with the date, lot number and concentration so that any later anomaly can be traced.

Frequently asked questions

What is the difference between GLP-1(7-36) amide and GLP-1(7-37)?

Both are active forms processed from proglucagon. GLP-1(7-36) amide has 30 residues and an amidated C-terminus, whereas GLP-1(7-37) has an extra C-terminal glycine and a free carboxyl group. Their masses differ, so a certificate of analysis should state exactly which form was supplied and show a matching mass.

Which receptor does GLP-1 act on?

GLP-1 binds the GLP-1 receptor, a class B G protein-coupled receptor with seven transmembrane domains, first cloned from rat pancreatic islets in 1992. In transfected cells it binds GLP-1 with high affinity and activates adenylate cyclase, raising cyclic AMP, which researchers measure in receptor-expressing cell lines.

Why is native GLP-1 so unstable in cell culture?

The enzyme dipeptidyl peptidase-4 cleaves the N-terminal His-Ala dipeptide, producing a fragment with much lower activity at the receptor, and the peptide is also cleared by other proteases. In serum-containing media its half-life can be very short, so researchers often use DPP-4 inhibitors, short incubations or stabilised analogues.

How should lyophilised GLP-1 be stored?

Keep the sealed vial dry, protected from light and at -20°C for long-term storage, and let it reach room temperature in a desiccator before opening. Because GLP-1 can aggregate in solution, divide reconstituted stock into single-use aliquots, freeze them promptly, and avoid repeated freeze-thaw cycles.

The compound discussed in this article is supplied for in-vitro laboratory research only and is not for human or veterinary use.

Leave a comment

99% Purity Guarantee
Trusted By Researchers
★★★★★
Celebrating 500,000 Orders
Third party verified